Skip to Content

Antares Pharma, Inc.

Merger

  • Date:
  • 4/13/2022
  • Company Name:
  • Antares Pharma, Inc.
  • Stock Symbol:
  • ATRS
  • Company Name - Buyer:
  • Halozyme Therapeutics, Inc.
  • Stock Symbol - Buyer:
  • HALO
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 4/13/2022

Case Finder

Locate any case using the tools below.

NEW YORK, April 13, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Antares Pharma, Inc. (NASDAQ: ATRS) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Halozyme Therapeutics, Inc. (NASDAQ: HALO).

On April 13, 2022, Antares announced that it had entered into an agreement to be acquired by Halozyme in a deal valued at approximately $960 million.  Pursuant to the merger agreement, Antares stockholders will receive $5.60 in cash for each share of Antares common stock owned.  The deal is scheduled to close in the first half of 2022.

Bragar Eagel & Squire is concerned that Antares’ board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Antares’ stockholders.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Antares Pharma. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: